Featured Research

from universities, journals, and other organizations

National Jewish Medical And Research Center Shows Rush Immunotherapy Results In Allergen-Specific Changes In T Cells

Date:
April 21, 1997
Source:
National Jewish Medical and Research Center
Summary:
Rush immunotherapy targeting a single allergen makes distinct changes in T cells and stops allergic reactions


National Jewish Medical and Research Center Shows Rush Immunotherapy Results in Allergen-Specific Changes in T Cells


DENVER-Rush immunotherapy targeting a single allergen makes distinct changes in T cells and stops allergic reactions, National Jewish Medical and Research Center physicians found, according to the April issue of the Journal of Allergy and Clinical Immunology.

"This study showed for the first time the T cell reaction to immunotherapy is specific," said Erwin Gelfand, M.D., head of the Department of Pediatrics at National Jewish and principal investigator of the study. "If you give too many antigens in desensitization, the immune system may not be able to distinguish between them. But attacking one trigger or a few triggers at a time can prevent the allergic reaction."
Rush immunotherapy consists of a number of injections given over a short time to desensitize a person to certain allergens, such as dust mites, cat dander or different types of plants.
Ten boys and girls, allergic to house dust mites and cat dander, were given rush immunotherapy for house dust mites only. When treatment ended, the children were desensitized to dust mites but not to cat dander, which showed that T cells can respond selectively to rush immunotherapy. In rush immunotherapy, T cells produce more interferon gamma, an element that lowers allergic responses, and shut off production of pro-allergic cytokines, which can cause wheezing, runny nose, sneezing and watery eyes.

"After rush immunotherapy you are more tolerant to an allergen you would have reacted to without desensitization," Dr. Gelfand said.

For more information on allergies, please call LUNG LINEβ, (800) 222-LUNG.


Story Source:

The above story is based on materials provided by National Jewish Medical and Research Center. Note: Materials may be edited for content and length.


Cite This Page:

National Jewish Medical and Research Center. "National Jewish Medical And Research Center Shows Rush Immunotherapy Results In Allergen-Specific Changes In T Cells." ScienceDaily. ScienceDaily, 21 April 1997. <www.sciencedaily.com/releases/1997/04/970421100734.htm>.
National Jewish Medical and Research Center. (1997, April 21). National Jewish Medical And Research Center Shows Rush Immunotherapy Results In Allergen-Specific Changes In T Cells. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1997/04/970421100734.htm
National Jewish Medical and Research Center. "National Jewish Medical And Research Center Shows Rush Immunotherapy Results In Allergen-Specific Changes In T Cells." ScienceDaily. www.sciencedaily.com/releases/1997/04/970421100734.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins